Merck & Co., Inc. Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations
Merck & Co., Inc. (MRK) reported Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations of $64.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations · last filed 2026-08-07
- Merck & Co., Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for the quarter ending 2025-06-30 was $146.00M, a 43.63% decline year-over-year.
- Merck & Co., Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for the quarter ending 2024-12-31 was $269.00M.
- Merck & Co., Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for the quarter ending 2024-09-30 was $0.00.
- Merck & Co., Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for the quarter ending 2024-06-30 was $259.00M.
- Merck & Co., Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2025 was $64.00M, a 87.88% decline from fiscal 2024.
- Merck & Co., Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2024 was $528.00M, a 915.38% increase from fiscal 2023.
- Merck & Co., Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2023 was $52.00M, a 30.00% increase from fiscal 2022.
- Merck & Co., Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2022 was $40.00M, a 31.03% decline from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 3 month | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 6 month | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 9 month | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month |
|---|---|---|---|---|
| 2025-12-31 | $64.00M 10-K · filed 2026-02-24 | |||
| 2025-06-30 | $146.00M 10-Q · filed 2026-08-07 | $146.00M 10-Q · filed 2026-08-07 | ||
| 2024-12-31 | $269.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $269.00M derived: sum of 2 quarters · filed 2026-02-24 | $528.00M derived: sum of 3 quarters · filed 2026-02-24 | $528.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $259.00M derived: sum of 2 quarters · filed 2025-11-05 | $259.00M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $259.00M 10-Q · filed 2025-08-05 | $259.00M 10-Q · filed 2025-08-05 | ||
| 2023-12-31 | $52.00M 10-K · filed 2026-02-24 | |||
| 2022-12-31 | $40.00M 10-K · filed 2025-02-25 | |||
| 2021-12-31 | $58.00M 10-K · filed 2024-02-26 | |||
| 2020-12-31 | $22.00M 10-K · filed 2023-02-24 | |||
| 2019-12-31 | $103.00M 10-K · filed 2022-02-25 | |||
| 2018-12-31 | $29.00M 10-K · filed 2021-02-25 | |||
| 2017-12-31 | $11.00M 10-K · filed 2020-02-26 | |||
| 2016-12-31 | $43.00M 10-K · filed 2019-02-27 | |||
| 2015-12-31 | $94.00M 10-K · filed 2018-02-27 | |||
| 2014-12-31 | $64.00M 10-K · filed 2017-02-28 | |||
| 2013-12-31 | $69.00M 10-K · filed 2016-02-26 | |||
| 2012-12-31 | $19.00M 10-K · filed 2015-02-27 | |||
| 2011-12-31 | $0.00 10-K · filed 2014-02-27 | |||
| 2010-12-31 | $14.00M 10-K · filed 2013-02-28 | |||
| 2009-12-31 | $3.00M 10-K · filed 2012-02-28 | |||
| 2008-12-31 | $9.00M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |